Project Grant R43DE031195

Award Date 12/1/21
Completion Date 11/30/22
Dollars Obligated $600K
Federal Grant Program
93.121
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This National Science Foundation (NSF) Cooperative Agreement award, provided through the NSF Technology, Innovation, and Partnerships (CFDA #47.084) program, funds the development of a novel, fully implantable craniofacial distraction system by Ostiio LLC, a medical device company based in Philadelphia, PA. The $1,000,000 award aims to produce a magnetic, subcutaneous distraction device capable of gradually correcting skeletal abnormalities affecting craniomaxillofacial functions such as...
This Project Grant award of $295,000.00 from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel implantable system leveraging distraction osteogenesis as a treatment for diabetic foot ulcers (DFUs). The project aims to design and develop a low-profile implantable transverse tibial transport device with an active mechanical mechanism to transversely distract or retract a cut tibia bone segment in a...
This $672,394.58 project grant from the National Institutes of Health's National Institute of Dental and Craniofacial Research Oral Diseases and Disorders Research program (CFDA 93.121) supports the development of a crosslinkable tissue particle implant for regenerating craniofacial bone. Led by Leefa Biotech LLC, the one-year award aims to demonstrate improved bone regeneration in critical-size cranial bone defects using the implant compared to the current standard of care. If successful, the...
Ostiio LLC received a $256,000 Project Grant award from the National Science Foundation on June 15, 2021 to support research and development activities concluding on May 31, 2022. The grant was awarded under the NSF's Engineering program (CFDA #47.041), which aims to improve quality of life and economic strength through engineering innovation and excellence. Specifically, the funding will support Ostiio's efforts to miniaturize a magnetic craniofacial distraction system. The company is located...
The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $250,931 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to Children's Mercy Hospital in Kansas City, Missouri. The grant will fund the development and validation of a novel diagnostic modality that integrates dynamic computed tomography (4D-CT) with computational fluid dynamics (CFD) analysis to quantify upper airway obstruction in patients with Robin sequence, a congenital...
The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $305,320 Project Grant to Mobius Biotech LLC to develop a novel 3D printed polycaprolactone (PCL) nasal graft called the Resorb3D Spreader Graft (RSG). This grant aims to evaluate the RSG's tissue integration, inflammatory response, and reconstruction efficacy compared to PDS plates, the currently available resorbable implant, in an...
This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) provides $305,000.00 to Magsorbeo Biomedical Corp to develop a bioabsorbable magnesium alloy for maxillofacial fixation. The project aims to create a magnesium-based implant that can provide temporary mechanical support during recovery and gradually be absorbed by the body, eliminating the need for secondary hardware removal surgeries. Key goals include demonstrating the...
This federal Project Grant award of $685,594 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to leverage microsurgery and bioprinting techniques to improve vascularization and survival of 3D printed or bioprinted bone grafts for craniomaxillofacial reconstructive surgery. The key products and services to be delivered include: Developing a novel microsurgical "vascular micropuncture"...
The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded Matregenix Inc. a $976,000 project grant (Award ID R44DE035026) to develop MATRINOVA, an animal-free, amino acid-based biodegradable barrier membrane for guided bone regeneration in dental and craniomaxillofacial surgeries. The goal is to establish the efficacy and clinical significance of MATRINOVA, a bilayered membrane produced using...
The National Institute of Child Health and Human Development (NICHD) awarded a $295,907 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to Liberating Technologies Inc. (LTI) to develop a prototype "Unintrusive Pediatric Logging Orthosis Analytic Device (UPLOAD)." The goal is to create a commercially viable, unobtrusive remote monitoring system for pediatric orthotics that can improve compliance tracking. Key features include long battery life, low...

A SMART, FULLY SUBCUTANEOUS DISTRACTION SYSTEM TO IMPROVE OUTCOMES IN PATIENTS WITH CONGENITAL OR ACQUIRED CRANIOFACIAL DIFFERENCES - SUMMARY / ABSTRACT EACH YEAR, ~200,000 NEWBORNS WORLDWIDE, 80-85% OF WHOM REQUIRE SURGICAL INTERVENTION, ARE AFFLICTED WITH CONGENITAL CONDITIONS THAT CAUSE IMPAIRED GROWTH OF THE SKULL OR MANDIBLE, LEADING TO ABNORMALITIES THAT AFFECT BREATHING, HEARING, SPEECH, VISUAL FUNCTION, NEUROLOGIC DEVELOPMENT, AND MASTICATION. UNFORTUNATELY, CURRENT SURGICAL TREATMENTS, INCLUDING ENDOSCOPIC SURGERY, OPEN RECONSTRUCTION, AND DISTRACTION OSTEOGENESIS (DO), SUFFER INHERENT DRAWBACKS, IMPACTING OUTCOMES. A BETTER SOLUTION IS NEEDED FOR THIS VULNERABLE PATIENT POPULATION. DO IS A WIDELY RECOGNIZED TREATMENT MODALITY THAT HARNESSES THE BODY'S NATURAL ABILITY TO REGENERATE BONE IN ORDER TO CORRECT SKELETAL DEFICIENCIES AND DEFECTS. WHILE STILL EMERGING FOR CRANIOMAXILLOFACIAL (CMF) APPLICATIONS, SURGEONS HAVE SHOWN THE UTILITY OF DO FOR RESTORING FUNCTIONAL DISCREPANCIES IN PATIENTS WITH CRANIOFACIAL DIFFERENCES. THE TECHNIQUE OF DO INVOLVES SURGICAL PLACEMENT OF ONE OR MORE DISTRACTORS, WHICH ARE DEVICES USED TO SLOWLY SEPARATE TWO OPPOSING BONY FRAGMENTS AT AN OSTEOTOMY SITE, TO GRADUALLY LENGTHEN AND RESHAPE THE AFFECTED BONE AND STIMULATE NEW BONE GROWTH. HOWEVER, DO IS NOT WITHOUT SHORTCOMINGS. FIRST, ALL CURRENT DISTRACTORS HAVE AN EXTERNAL COMPONENT FOR MANUAL EXPANSION. THE EXTERNAL COMPONENT SIGNIFICANTLY INCREASES PATIENT RISK FOR COMPLICATIONS SUCH AS INFECTION (35%), DEVICE DISLODGEMENT (3.0%), INCREASED ANALGESIC USE, AND SCARRING (15.6%). SECOND, SINCE THE BURDENSOME RESPONSIBILITY FOR MANUAL EXPANSION LIES WITH THE CAREGIVER, TREATMENT NONCOMPLIANCE (4.7%) IS A SERIOUS ISSUE, INTRODUCING VULNERABILITIES RANGING FROM INCONSISTENT DEVICE EXPANSION TO COMPLETE TREATMENT FAILURE. THEREFORE, DO NECESSITATES EXTENSIVE PHYSICIAN CLINIC TIME AND PATIENT RADIATION EXPOSURE TO MONITOR THERAPEUTIC PROGRESS AND THUS HAS NOT BEEN WIDELY ADOPTED IN THE CMF SKELETON DESPITE RECOGNITION OF POTENTIAL ADVANTAGES OVER ENDOSCOPIC SURGERY (NARROWER INDICATION FOR USE) AND OPEN RECONSTRUCTION (MORE INVASIVE, LONGER ANESTHESIA TIME, HIGHER BLOOD TRANSFUSION RATE, LONGER HOSPITAL STAY). THE OSTIIO DISTRACTION (OD) SYSTEM ADDRESSES MANY OF THE ISSUES ASSOCIATED WITH DO TREATMENT AS THE FIRST FULLY SUBCUTANEOUS, CONTACTLESS DO SYSTEM FOR THE CMF SKELETON. AT A HIGH LEVEL, THE OD SYSTEM LEVERAGES MAGNETIC COUPLING TO TRANSFER TORQUE FROM THE HAND-HELD DRIVER (HHD) TO THE IMPLANT, THEREBY EXPANDING THE IMPLANT IN A CONTACTLESS FASHION. THIS NOVEL APPROACH WILL MARKEDLY REDUCE INFECTION, SCARRING, AND MANIPULATION NONCOMPLIANCE. IN ADDITION, BECAUSE THE DESIGN UNIQUELY PERMITS WIRELESS COMMUNICATION BETWEEN THE IMPLANT AND HHD, IT WILL ENABLE PHYSICIANS TO BETTER CONTROL AND MONITOR TREATMENT PROGRESS. THIS PROPOSAL AIMS TO VALIDATE A KEY PERFORMANCE SPEC OF THE OD SYSTEM BY DEMONSTRATING IT CAN RIGOROUSLY MEET DISTRACTION FORCE PERFORMANCE PARAMETERS SIMILAR TO THOSE ACHIEVED BY THE CURRENT STANDARD OF CARE. SUCCESSFUL DEMONSTRATION OF THIS OUTCOME WILL SUPPORT PHASE II IN WHICH WE WILL FURTHER DEVELOPMENT OF THE OD SYSTEM BY VALIDATING FUNCTION AND PERFORMANCE IN AN IN VIVO MODEL AND FORMATIVE HUMAN FACTORS STUDY. THIS WORK WILL SPEED TO MARKET A NOVEL APPROACH TO CMF SURGERY THAT CAN SIGNIFICANTLY IMPROVE DO PATIENT OUTCOMES AND EXPERIENCE.

Posted 12/1/21